Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Deep Informatics++ Closes $14 Million Series B for AI-based Pathology Products

publication date: Jun 3, 2020

Deep Informatics++ of Hangzhou, a company that offers AI-based pathology products, completed a Series B financing of over $14 million. Founded in January 2017, Deep Informatics++ uses proprietary AI algorithms to develop multi-module diagnostic tools. Its products include: D-CleverEye (adds AI analysis to a microscope), D-PathAI (AI-assisted pathology diagnosis), and DPathAIS (an AI-based workstation). The round was led by CICC Fengtai Fund, a China Capital Investment Group fund, with participation from Legend Capital and Jiangmen Venture Capital. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here